Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: Randomised placebo-controlled trial

British Journal of Psychiatry

Volumn 192, Issue 3, 2008, Pages 217-223

  Stubhaug, Bjarte ^a   Lie, Stein Atle ^b   Ursin, Holger ^b   Eriksen, Hege R ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; PLACEBO;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURASTHENIA; PATIENT REFERRAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; NEURASTHENIA; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 40449094227     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.106.031815     Document Type: Article

References (29)

1. Beard G. Neurasthenia, or nervous exhaustion. Boston Med Surg J 1869; 3: 217-21.
2. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones SF, Dubois RE, Cunningham-Rundles C, Pahwa S. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387-9.
3. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, Edwards RH, Hawton KE, Lambert HP, Lane RJ, McDonald EM, Mowbray JF, Pearson DJ, Peto TEA, Preedy VR, Smith AP, Smith DJ, Taylor DJ, Tyrrell DA, Wessely S, White PD. A report - chronic fatigue syndrome: guidelines for research. J R Soc Med 1991; 84: 118-21.
4. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-9.
5. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286: 1360-8.
6. Chambers D, Bagnall AM, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med 2006; 99: 506-20.
7. Stubhaug B, Tveito TH, Eriksen HR, Ursin H. Neurasthenia, subjective health complaints and sensitization. Psychoneuroendocrinology 2005; 30: 1003-9.
8. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry 1990; 156: 534-40.
9. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet w, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000; 48: 75-8.
10. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25: 677-9.
11. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17 (suppl 1): S19-28.
12. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999; 57: 607-31.
13. Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR, von Giesen JH. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006; 22: 257-64.
14. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37: 168-70.
15. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. WHO, 1993.
16. World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry (SCAN), WHO, 1992.
17. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-53.
18. Eriksen HR, Ihlebaek C, Ursin H. A scoring system for subjective health complaints (SHC). Scand J Public Health 1999; 27: 63-72.
19. Ware JE, Snow KK, Kosinski M. SF-36 Health Survey Manual and Interpretation Guide. QualityMetric Inc, 2000.
20. Loge JH, Kaasa S, Hjermstad MJ, Kvien TK. Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol 1998; 51: 1069-76.
21. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of ver 1. QualityMetric Inc, 2001.
22. Guy W. CGI Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology (Revised) 217-22. National Institute for Mental Health, 1976.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96.
25. Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002; 17: 1-16.
26. Astrand PO, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during sub-maximal work. J Appl Physiol 1954; 7: 218-21.
27. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-17.
28. Skatteboe UB, Friis S, Hope MK, Vaglum P. Body awareness group therapy for patients with personality disorders. 1. Description of the therapeutic method. Psychother Psychosom 1989; 51: 11-17.
29. van Mens-Verhulst J, van Dijkum C, van Kuijk E, Lam N. The self-regulation of fatigue and associated complaints: an exploratory simulation. Patient Educ Couns 2003; 49: 53-7.